A clinical feasibility trial for identification of exceptional responders in whom breast cancer surgery can be eliminated following neoadjuvant systemic therapy

HM Kuerer, GM Rauch, S Krishnamurthy… - Annals of …, 2018 - journals.lww.com
Objective: To determine the accuracy of fine-needle aspiration (FNA) and vacuum-assisted
core biopsy (VACB) in assessing the presence of residual cancer in the breast after …
被引用次数：184 相关文章

[引用][C] A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic …

HM Kuerer, GM Rauch, S Krishnamurthy, BE Adrada… - Annals of …, 2018 - cir.nii.ac.jp
A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer
Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy | CiNii Research CiNii …
[HTML] nih.gov

[HTML][HTML] A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic …

HM Kuerer, GM Rauch, S Krishnamurthy… - Annals of …, 2018 - ncbi.nlm.nih.gov
A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast
Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy - PMC Back …

A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy

HM Kuerer, GM Rauch, S Krishnamurthy… - Annals of …, 2018 - pubmed.ncbi.nlm.nih.gov
Objective To determine the accuracy of fine-needle aspiration (FNA) and vacuum-assisted
core biopsy (VACB) in assessing the presence of residual cancer in the breast after …

A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy.

HM Kuerer, GM Rauch, S Krishnamurthy… - Annals of …, 2018 - europepmc.org
A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer
Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy. - Abstract - Europe …

A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy

HM Kuerer, GM Rauch… - Annals of …, 2018 - mdanderson.elsevierpure.com
Objective: To determine the accuracy of fine-needle aspiration (FNA) and vacuum-assisted
core biopsy (VACB) in assessing the presence of residual cancer in the breast after …

A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy.

HM Kuerer, GM Rauch, S Krishnamurthy… - Annals of …, 2018 - europepmc.org
A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer
Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy. - Abstract - Europe …